Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Exposure Bioequivalence of BGF MDI HFO vs HFA
NCT05477108Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Drug Concentration, Area Under Plasma Concentration Time Curve From Zero to Infinity and 1 more. Started Jul 2022; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05477108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477108.